David Bartkovitz

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Qingjie Ding, Zhuming Zhang, Jinjun Liu et al. · Journal of Medicinal Chemistry · 2013 · 583 citations · Full text

Drug Target, Chemical Biology, Cancer Biology +19

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), A Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significant in Vivo Antitumor Activity

Xin‐Jie Chu, Wanda DePinto, David Bartkovitz et al. · Journal of Medicinal Chemistry · 2006 · 116 citations · Full text

Drug Target, Pharmacotherapy, Cell Cycle +17

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

Zhuming Zhang, Xin‐Jie Chu, Jinjun Liu et al. · ACS Medicinal Chemistry Letters · 2013 · 86 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Chemoprevention Strategy +14

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

Zhuming Zhang, Qingjie Ding, Jinjun Liu et al. · Bioorganic & Medicinal Chemistry · 2014 · 55 citations

Cancer Therapy, Medicinal Chemistry, Oncology +9

Identification of novel, potent and selective inhibitors of Polo-like kinase 1

Shaoqing Chen, David Bartkovitz, Jianping Cai et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 33 citations

Signaling Pathway, Medicine, Receptor Tyrosine Kinase +9